Funding Daily Summary: What Happened on October 19, 2026

Nouscom funds global trial plans for NOUS-209

Nouscom closed an oversubscribed €120 million Series D to advance NOUS-209, a vaccine intended to prevent cancer in people with Lynch syndrome.1 M Ventures and Revelation Partners co-led the round, joined by Angelini-related investors, the European Investment Bank and Neva SGR.1

CEO Marina Udier said Nouscom plans to move NOUS-209 into one global registration-enabling trial.1 Udier said the trial’s primary endpoint will be event-free survival, counting precancerous events and cancer, and that the design has been discussed with the FDA and European Medicines Agency.1

Long-term findings from a Phase 1b/2 study in people with Lynch syndrome are scheduled for presentation at the ESMO Congress on October 25.1 Preventive benefit has not yet been demonstrated in a controlled trial.1 The FDA has granted NOUS-209 Fast Track designation.1

Estuary launches with $103 million for kidney gene therapies

Estuary Biotherapeutics launched with $103 million in committed financing, including a $93 million Series A and an earlier $10 million seed round.2 RA Capital Management led the Series A. Seed investors 4BIO Capital and GV also participated.2

The company plans to fund clinical proof-of-concept work on EST-101 and EST-201 and advance a platform that delivers adeno-associated virus (AAV) vectors directly to kidney cells.2 Local delivery is intended to restore polycystin levels across the nephron while avoiding problems associated with systemic AAV delivery.2

EST-201, an AAV-delivered PKD2 gene therapy, is scheduled to enter clinical development in 2027.2 EST-101 targets the PC1 functional region for people with PKD1 mutations and is projected to begin clinical testing in 2028.2

Also published

• Fresenius Ventures’ managing director: Europe has the investors. It needs the capital. European Biotechnology
• Cancer biotech Nouscom adds €120m, and other financings pharmaphorum